Abstract. Besides in the brain, corticotropin-releasing hormone occurs in the pancreas. Therefore, its effects on plasma levels of insulin and glucagon were investigated in vivo in the mouse. At 2 min after CRH injection (0.5\p=n-\8.0 nmol/kg), plasma insulin was lowered: by 4.0 nmol/kg from 38 \ m=+-\4 to 28 \ m=+-\2 mU/l (P < 0.05). Plasma insulin was lowered also at 6 min, whereas at 10 min, plasma insulin levels were elevated (P < 0.05). Plasma glucagon levels were slightly lowered (P < 0.05) at 10 min after CRH injection, whereas plasma glucose was slightly elevated (P < 0.05) at 6 min after injection but not at 2 or 10 min. The effects of CRH on the plasma insulin and glucagon response to iv injections of half-maximal dose levels of glucose (2.8 
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CRH was recently demonstrated also within the pancreas (Petrusz et al. 1983) . That study showed that the peptide was a constituent of peripherally located endocrine-like cells of the rat, mouse, cat, chicken and human pancreas (Petrusz et al. 1983 ).
The CRH cells were found to be distinct from the cells producing insulin, pancreatic polypeptide (PP), and somatostatin, but a topographical over¬ lap was seen between CRH and glucagon-producing cells (Petrusz et al. 1983) . A subsequent immunocytochemical study localized islet CRH immunoreactivity in nerves too (Moltz et al. 1985) . Since intrapancreatic peptides and nerves pre¬ viously have been shown to be of importance for islet hormone secretion ), the hypothesis may therefore be put forward that also CRH is involved in the regulation of the secretion of the islet hormones. Thus, previous studies on the effects of CRH on the release of PP have consistently shown that CRH is able to stimulate PP secretion both in man (Lytras et al. 1984 ) and in dogs (Konturek et al. 1985 (Ahrén & Lundquist 1981 ).
Determinations oj insulin, glucagon and glucose Plasma levels of immunoreactive insulin and glucagon were determined radioimmunochemically (Heding 1966; Ahrén 8c Lundquist 1982a) . The antiserum used for the determination of plasma glucagon is specific for pancreatic glucagon (Milab, Malmö, Sweden) . Plasma glucose levels were determined with the glucose oxidase method (Bruss & Black 1978 (Fig. 1) . Fig. 2 shows the plasma levels of insulin, glu¬ cagon and glucose at 2, 6, and 10 min after injection of CRH at a concentration of 4.0 nmol/ kg. It is seen that compared with controls, plasma insulin levels were lowered at 2 and 6 min by CRH: at 2 min, they were 38 ± 4 mU/1 in controls and 28 ± 2 mU/1 in animals given CRH (P < 0.05), and at 6 min after injection 54 ± 5 mU/1 in controls against 37 ± 5 mU/1 in the CRH group (P < 0.05). At 10 min after injection, plasma insulin levels were higher in CRH-injected ani- (Moltz & Fawcett 1985a (Moltz & Fawcett 1985b) . In some series of experiments we observed enhancement of plasma glucagon levels after injection of CRH.
However, the degree of significance was low (Fig. 2) , which probably explains why this effect was not visible in other series (Fig. 3) . In com¬ bination with the lowered basal plasma insulin levels, the slight hyperglucagonaemia could result in hyperglycaemia, which, though slight, was regularly observed at 6 min after injection and in some animals also at 2 min after injection. This pattern of alterations, hypoinsulinaemia, hyper¬ glucagonaemia and hyperglycaemia, is commonly seen during stress ) and it might therefore be suggested that CRH is of some importance for the regulation of basal levels of insulin and glucagon during stress. However, the low potency of the effects of CRH suggests that this peptide is of no great importance. It is of interest that the effects of CRH demonstrated in the present study after peripheral injection of the peptide resemble those found after intracerebro¬ ventricular administration (Brown et al. 1982 ).
This might imply that CRH induces hypergly¬ caemia, hyperglucagonaemia, and hypoinsulinaemia both through central and peripheral actions.
CRH did not affect the insulin or glucagon resonses to iv injections of glucose and the cho¬ linergic agonist carbachol. Since the doses used for glucose and carbachol are not maximal doses (Ahrén & Lundquist 1981 , 1982b 
